Triatomic Management’s GeneDx Holdings WGS Stock Holding History

Triatomic Management’s Portfolio WGS Stock Details WGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-939	Closed	-$138K	–	55
2021 Q4	$138K	Buy	+939	New	+$210K	0.08%	39

Other funds holding WGS

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Corvex Management New York $3.27B AUM 38.53% 1-Year Est. Return

Third Point New York $4.68B AUM 37.3% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Triatomic Management's WGS Position: Q1 2022 in Review

Triatomic Management sold out of GeneDx Holdings (WGS) in Q1 2022, closing a stake of 939 shares — an estimated $138K sold.

Triatomic Management first reported a position in WGS in Q4 2021 and held it in 1 quarter. The position peaked at $138K in Q4 2021. 108 funds tracked by Wall St. Rank hold WGS as of Q1 2022.

Triatomic Management reported no remaining GeneDx Holdings position as of Q1 2022 after selling out during the quarter.
Triatomic Management sold 939 GeneDx Holdings shares in Q1 2022, an estimated $138K.
Triatomic Management first reported a position in GeneDx Holdings in Q4 2021 and held it in 1 quarter.
Triatomic Management's GeneDx Holdings position peaked at $138K in Q4 2021.
108 funds tracked by Wall St. Rank held GeneDx Holdings as of Q1 2022.

Based on Triatomic Management's 13F filing for Q1 2022, filed 12 May 2022.